News
Resources
Blog
Sites
New research: Insurance plan structure can have discriminatory effect
By Karyn Schwartz | March 31, 2016
New research from the Harvard University Center for Health Law and Policy Innovation (CHLPI) is another piece of evidence showing how health insurance plan design may be trying to discourage...
Read More
Fighting the Zika virus - A lesson for defending against emerging pathogens
By Guest Contributor | March 30, 2016
Dr. Gary J. Nabel, Chief Scientific Officer, Global Research & Development – Sanofi In recent months, Zika virus has emerged as a global public health concern. Discovered in 1947 in Uganda, Zika...
Read More
America’s biopharmaceutical industry is central to diverse R&D ecosystem
By Andrew Powaleny | March 29, 2016
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that supports continued medical advances for patients. This includes small and large...
Read More
Medicare Monday: Advancing treatments for osteoporosis with medicines in development
By Nicole Longo | March 28, 2016
Since the implementation of Medicare Part D, we’ve seen numerous signs of success when it comes to how the program works and how it helps seniors and individuals with disabilities live longer,...
Read More
Week in review: The latest from PhRMA
By Priscilla VanderVeer | March 25, 2016
FDA quality metrics: Building on our constructive ideas for improvements to the FDA’s recent proposal for a mandatory metrics program, we featured a guest blog post from Mairead Goetz, head of...
Read More
Proposed quality metrics program raises operability questions
By Guest Contributor | March 25, 2016
Previously in this blog series, we’ve discussed PhRMA’s main recommendation for a phased-in approach to the U.S. Food and Drug Administration’s (FDA) proposed quality metrics program, as well as...
Read More
Looking back at a decade of advancements in MS treatments
By Nicole Longo | March 21, 2016
Have you ever met someone, become friends with someone and then found out they were living with a debilitating disease, and you couldn’t tell? I never would have guessed a friend of mine was living...
Read More
Medicare Monday: What Part D Extra Help means to patients like Diane
By Nicole Longo | March 21, 2016
As part of our Medicare Monday series, we have looked at how changes to Medicare Part D’s Extra Help program, also known as the low-income subsidy, would negatively impact beneficiaries. We’ve also...
Read More
Week in Review: The latest from PhRMA
By Priscilla VanderVeer | March 18, 2016
ICYMI: Policy solutions for innovative treatment: Last week at our 2016 Annual Meeting, our president and CEO Steve Ubl discussed his vision for the organization and outlined policy solutions for...
Read More
What “value” means to me
By Priscilla VanderVeer | March 17, 2016
It’s March, which means it is National Kidney Month. More than 661,000 Americans have kidney failure. Every day, approximately 13 people die waiting for a kidney transplant. I am lucky to not be one...
Read More
Ask About Adherence: Q&A with Christiana Care Health System’s Value Institute
By Samantha Dougherty | March 17, 2016
Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Dominique Comer, Pharm.D., MS, senior clinical investigator and scholar with...
Read More
Research doesn’t end on a medicine’s approval
By Andrew Powaleny | March 16, 2016
Research is a critical part of the development of new medicines, but it doesn’t stop once the medicine is approved by the U.S. Food and Drug Administration (FDA). In fact, that’s when post-approval...
Read More
Transparency and confidentiality in FDA’s proposed quality metrics proposal is key
By Sarah Spurgeon | March 15, 2016
In our last post on this topic, we discussed PhRMA member companies’ commitment to quality and introduced you to the U.S. Food and Drug Administration’s (FDA) proposed mandatory quality metrics...
Read More
Clinical Trials Q&A: Income disparities
By Jocelyn Ulrich | March 14, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: 3 things to know about the government’s Medicare payment change
By Allyson Funk | March 14, 2016
Last week, the Centers for Medicare & Medicaid Services (CMS) released a proposed demonstration through the Innovation Center to change how Medicare Part B drugs are reimbursed. Here are the three...
Read More
Fighting blood cancers together at the 2016 Leukemia Ball
By Josephine Martin | March 11, 2016
Tomorrow, the Leukemia & Lymphoma Society (LLS) will hold one of Washington, D.C.’s largest charitable events: the 2016 Leukemia Ball. Since it began in 1988, the annual event has raised nearly $50...
Read More
ICYMI: Policy solutions for delivering innovative treatments to patients
By Robert Zirkelbach | March 11, 2016
Yesterday, at the PhRMA 2016 Annual Meeting, PhRMA president and CEO Steve Ubl laid out his vision for the organization and released policy solutions for delivering innovative treatments to patients.
Read More
Tearing down barriers to cooperation with strengthened intellectual property protections
By Guest Contributor | March 11, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Tune in now to the PhRMA 2016 Annual Meeting
By Josephine Martin | March 9, 2016
Today at 4:00 p.m. will mark the start of the PhRMA 2016 Annual Meeting here in Washington, D.C. Click below to watch events so far. Over the next two days, we’ll hear from speakers from across the...
Read More
Past free trade agreements provide valuable lessons for future success
By Jay Taylor | March 8, 2016
Last week, the Senate Committee on Finance held a hearing to discuss free trade agreement implementation and lessons learned from past agreements. The hearing focused on recent examples where...
Read More
Medicare Monday: Part D coverage then and now
By Allyson Funk | March 7, 2016
In the last couple of weeks, we’ve explored what was said about Medicare Part D costs, beneficiary premiums and competition when the program was created – and at what has actually happened in the...
Read More
New PhRMA Report: Medicines in development offer hope for osteoporosis patients and families
By Ieva M. Augstums | March 7, 2016
Americans are living longer lives, and our aging population is growing. That’s exciting news – but that also means more and more Americans are at risk of a broken bone as a result of osteoporosis or...
Read More
Week in Review: The latest from PhRMA
By Priscilla VanderVeer | March 4, 2016
Communications with health care professionals – A new paper from the Duke-Margolis Center for Health Policy rightly makes the argument in favor of establishing a more effective regulatory framework...
Read More
Today, the wealth of information about medicines is more comprehensive and complex than ever before. Scientific knowledge and new findings go far beyond the parameters established by Food and Drug...
Read More
Time to enforce the rules that protect American ideas, brands and inventions
By Chris Moore | March 1, 2016
Earlier today, PhRMA joined organizations representing every sector of America’s knowledge economy at a public hearing in Washington that will inform the federal government’s annual “Special 301”...
Read More
5 facts about the PhRMA Foundation
By Eileen Cannon | March 1, 2016
As the PhRMA Foundation celebrates its 50th year, here are five facts about the PhRMA Foundation and its work to support young pharmaceutical scientists across the United States. For young...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
